Inova Software Secures Additional Funding from Its Founders and NextStage AM to Support Its Strong Growth
In a financial deal of 6M€, NextStage AM takes a stake in Inova Software, a SaaS partnering platform for pharmaceutical and biotechnology companies, to further boost its growth.
Inova Software develops a SaaS partnering platform that facilitates collaborations between pharmaceutical and biotechnology companies. Inova Software’s solutions are used by over 120 companies, including half of the top 50 pharmaceutical companies, such as Roche, Novartis, Lilly and Bayer, to manage their external partnerships and accelerate their therapeutic advances.
The life sciences industry is undergoing a strong push towards partnering, driven by their need to innovate. Wanting to capitalize on this opportunity for growth, Inova Software is welcoming NextStage AM as a new shareholder. Inova Software’s Annual Recurrent Revenue has grown 30% year to year over the past 3 years and is expected to exceed 6 million euros this year. With this new financing, Inova Software anticipates even faster growth through:
- Inova Partnering Platform , covering the entire partnering lifecycle: Widely used by the business development and alliance management teams, Inova’s partnering platform is being adopted by more departments, such as R&D, M&A and manufacturing. These departments are all increasing their activities with external partners.
- Inova One-on-One Partnering, the digital networking solution for conferences: Since 2015, the Biotechnology Innovation Organization (BIO) and Inova have facilitated exchanges between life science companies during the industry’s biggest conferences. In 2018, for example, this solution enabled over 45,000 business meetings to be organized at BIO’s annual convention in Boston, USA. Based on its success, more and more life science events are adopting Inova’s networking solution.
By teaming up with NextStage AM, Inova Software will unleash its ability to innovate, reinforce its marketing investments, and execute acquisitions. Inova Software has offices in Lyon, New York and Tokyo. The company currently employs 50 people and plans to recruit an additional 15 employees in 2019. Inova Software generates over 90% of its turnover outside of France (including 45% in the United States) and expects to see its recurring revenue grow 40% in 2019.
“NextStage AM is a great fit for Inova. We were attracted by their strong entrepreneur/investor culture and enthusiasm for our ambitious, groundbreaking projects,” explained Gilles Toulemonde, CEO and co-founder of Inova Software.
“Inova Software manages to be both a leading player and a disruptive one in an industry that is undergoing an enormous amount of upheaval. This industry is reinventing itself and Inova Software has everything it takes to grow and become a strategic partner of top biopharma companies. We are proud to be able to accompany Inova over the long term,” added Nicolas de Saint Etienne, Partner, NextStage AM.
Inova provides a cloud-based software and services for life sciences companies to better manage their partnering lifecycle. By using Inova our clients manage their biopharma opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily and report on their pipeline and activities in seconds.
We have also developed strategic partnerships that make data from the 20 biggest biopharma events automatically available in Inova, providing our users with always up-to-date company and contact information. Over 120 life science companies, including 50% of the top 50 pharmaceutical companies and many midsize pharma and biotechs already use Inova. We are headquartered in Lyon, France, and also operate offices in New York and Tokyo. For more information, visit www.inova-software.com
Based in Paris, NextStage AM is a leading growth equity firm. NextStage AM invests in a limited number of innovative French and European medium-sized businesses, bringing an entrepreneur/investor expertise and significant operational and international experience. NextStage AM provides these companies with the means to accelerate their development and their ability to innovate in order to become champions of their industry, in France and globally, through organic and/or external growth. For more information, visit www.nextstage.com
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Telna Launches New eSIM Solution at MWC Barcelona 201924.2.2019 00:00:00 | Pressemelding
Telna, a vertically integrated Network-as-a-Service (NaaS) provider of global end-to-end connectivity solutions, today is adding eSIM technology to its platform. The new resilient and efficient eSIM architecture will be showcased at Mobile World Congress Barcelona 2019, from February 25th - February 28th at Telna’s booth in Hall 1, Stand 1B80. “eSIM technology is another example of a global trend in digital transformation set to disrupt cellular connectivity,” says Gregory Gundelfinger, CEO of Telna. “Our customers now have access to both Consumer and IoT/M2M eSIM that is bundled with the rest of our software-defined network services.” eSIM is an embedded SIM card, meaning there is no physical SIM card and no physical swapping of SIM cards. It's easy to add data plans and is endorsed by the GSMA. “The virtualization of the SIM card removes one of the largest barriers when switching between networks, the physical SIM card,” says Gundelfinger. The Telna eSIM allows users to access their
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00 | Pressemelding
Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00 | Pressemelding
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00 | Pressemelding
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00 | Pressemelding
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of